Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma. / Fominykh, M. S.; Shuvaev, V. A.; Voloshin, S. V.; Schmidt, A. V.; Kuvshinov, A. Y.; Kuzyaeva, A. A.; Zapreeva, I. M.; Abdulkadyrov, K. M.
в: Genes and Cells, Том 9, № 2, 01.01.2014, стр. 38-41.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma
AU - Fominykh, M. S.
AU - Shuvaev, V. A.
AU - Voloshin, S. V.
AU - Schmidt, A. V.
AU - Kuvshinov, A. Y.
AU - Kuzyaeva, A. A.
AU - Zapreeva, I. M.
AU - Abdulkadyrov, K. M.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the one of the effective therapy for patients with multiple myeloma. The aim of our study was to investigate the efficacy and safety of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients. Ten patients with multiple myeloma underwent autologous hematopoietic stem cell transplantation with romiplostim support (romiplostim group). All the patients received 250 μg of the thrombopoietin receptor agonist romiplostim on day of hematopoietic stem cell reinfusion. Thirty patients with multiple myeloma were assessed as a control group (without romiplostim support). The duration of grade 4 thrombocytopenia was 4.0 days for romiplostim group and 7.4 days for the control group (p = 0.003). Time to platelet count >25×109/l was 10.4 days for romiplostim group and 13.0 days for the control group (p = 0.002). Platelet transfusion volume was 980 ml for romiplostim group and 1376 ml for the control group. Safety and efficacy of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients had proven by reduced risk of bleeding and cost minimization.
AB - High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the one of the effective therapy for patients with multiple myeloma. The aim of our study was to investigate the efficacy and safety of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients. Ten patients with multiple myeloma underwent autologous hematopoietic stem cell transplantation with romiplostim support (romiplostim group). All the patients received 250 μg of the thrombopoietin receptor agonist romiplostim on day of hematopoietic stem cell reinfusion. Thirty patients with multiple myeloma were assessed as a control group (without romiplostim support). The duration of grade 4 thrombocytopenia was 4.0 days for romiplostim group and 7.4 days for the control group (p = 0.003). Time to platelet count >25×109/l was 10.4 days for romiplostim group and 13.0 days for the control group (p = 0.002). Platelet transfusion volume was 980 ml for romiplostim group and 1376 ml for the control group. Safety and efficacy of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients had proven by reduced risk of bleeding and cost minimization.
KW - Autologous stem cell transplantation
KW - High-dose chemotherapy
KW - Multiple myeloma
KW - Romiplostim
UR - http://www.scopus.com/inward/record.url?scp=84926466486&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84926466486
VL - 9
SP - 38
EP - 41
JO - Гены и клетки
JF - Гены и клетки
SN - 2313-1829
IS - 2
ER -
ID: 46138223